The future of the global post-traumatic stress disorder (PTSD) market looks promising with opportunities in the hospital and clinic markets. The global post-traumatic stress disorder (PTSD) market is expected to reach an estimated $1.4 billion by 2030 with a CAGR of 4.6% from 2024 to 2030. The major drivers for this market are increasing prevalence of post-traumatic stress disorders, rising awareness towards mental health issues, and growing demand of mental health services along with surhing R&D activities for treatment of post-traumatic stress disorders.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the post-traumatic stress
disorder (PTSD) market by product type (antidepressants, cognitive therapy,
anti-anxiety drugs, exposure therapy, eye movement desensitization &
reprocessing (EMDR), and PSTD therapeutics), age group (children and adult),
end use (hospitals and clinics), and region (North America, Europe, Asia
Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, children
and adult are the major segments of post-traumatic stress disorder (PTSD) market
by age group. Lucintel forecasts that adult will remain the larger semgent over
the forecast period due to large number of patients in this age group, growing
mental health disorder cases in the adult group, and rising traumatic
experiences.
Within this market,
hospitals will remain the larger segment due to their importance in primary
healthcare settings for the diagnosis and treatment of post-traumatic stress
disorder cases along with their capabilities to manage acute crisis.
North America will remain
the largest region due to increasing prevalence of post-traumatic stress
disorder and growing demand of mental healthcare services in the region.
Glaxosmithkline, Pfizer,
Eli Lilly & Company, Azevan Pharmaceuticals, Otsuka Pharmaceutical,
Astrazeneca, Neurocrine Biosciences, Nuvo Pharmaceuticals, Marinus
Pharmaceuticals, and Tonix Pharmaceuticals are the major suppliers in the
post-traumatic stress disorder (PTSD) market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment